↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Poulsen P) ;mspu:(article)"

Search: WFRF:(Poulsen P) > Journal article

Result 1-10 of 321

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
2.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
3.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
4.	Steg, PG, et al. (author) Effect of Alirocumab on Mortality After Acute Coronary Syndromes 2019 In: Circulation. - 1524-4539. ; 140:2, s. 103-112 Journal article (peer-reviewed)
5.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
6.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
7.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
8.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
9.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
10.	Ruilope, LM, et al. (author) Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial 2019 In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356 Journal article (peer-reviewed)abstract <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 321

Refine your search

Type of publication: journal article (321)Undo refine

Type of content: peer-reviewed (316); other academic/artistic (5)

Author/Editor: Ellert, Mattias (164); Brenner, Richard (163); Ekelöf, Tord (163); Strandberg, Jonas (162); Zwalinski, L. (160); Ripellino, Giulia (159); show more...; Sidebo, P. Edvin (151); Moa, Torbjörn (148); Clement, Christophe (148); Milstead, David A. (148); Sjölin, Jörgen (148); Hellman, Sten (147); Shaikh, Nabila W. (147); Wallängen, Veronica (147); Bocchetta, Simona (145); Poulsen, Trine (145); Åkesson, Torsten (144); Doglioni, Caterina (144); Hedberg, Vincent (144); Jarlskog, Göran (144); Lytken, Else (144); Mjörnmark, Ulf (144); Smirnova, Oxana (144); Bokan, Petar (142); Kalderon, Charles (140); Pöttgen, Ruth (137); Jon-And, Kerstin (136); Ughetto, Michaël (134); Silverstein, Samuel ... (132); Gradin, P.O. Joakim (131); Mankinen, Katja (129); Bergeås Kuutmann, El ... (129); Carney, Rebecca M. D ... (127); Bertoli, Gabriele (124); Ferrari, Arnaud, 197 ... (123); Lund-Jensen, Bengt (122); Valdés Santurio, Edu ... (122); Molander, Simon (119); Kellermann, Edgar (118); Kastanas, Konstatino ... (114); Gellerstedt, Karl (113); Isacson, Max (100); Viazlo, Oleksandr (96); Bessidskaia Bylund, ... (92); Konya, Balazs (90); Öhman, Henrik (89); Sales De Bruin, Pedr ... (88); Bohm, Christian (84); Aad, G (82); Abulaiti, Yiming (77); show less...

University: Lund University (207); Uppsala University (180); Royal Institute of Technology (163); Stockholm University (155); Karolinska Institutet (85); University of Gothenburg (19); show more...; Chalmers University of Technology (17); Linköping University (8); Umeå University (4); Mid Sweden University (2); Halmstad University (1); Örebro University (1); Jönköping University (1); Högskolan Dalarna (1); Swedish University of Agricultural Sciences (1); show less...

Language: English (321)

Research subject (UKÄ/SCB): Natural sciences (195); Medical and Health Sciences (56); Engineering and Technology (12); Agricultural Sciences (1); Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view